Ally Bridge Group is a global healthcare investment management firm focused on high-impact life science innovation across private and public markets. Founded in 2013 by Frank Yu, the firm manages assets from offices in New York and Hong Kong.
41% of their portfolio is in Healthcare. Average disclosed round size is $125.9M (across 53 rounds with reported amounts).
Portfolio
47
Fund Size
—
Top Stage
Series D
Last 12 Mo
4
Team
AL
Andrew Lam, PharmD
Managing Director, Head of Biotech
CW
Charles Wong, CPA
Managing Director, Chief Operating Officer, Chief Financial Officer
EY
Emma Yang
Director of Legal
CS
Carlos Solorzano, PhD
Principal
JW
Jonathan Wang, CFA, CPA
Vice President
KC
Kelly Cheng, CPA
Vice President
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
58 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Biobeat | Series B | $50M | Jan 2026 |
 Solve Therapeutics | Unknown | $120M | Jan 2026 |
| BBiobeat Technologies | Series B | $50M | Dec 2025 |
| Solve Therapeutics | Series D | $120M | Nov 2025 |
 Galvanize Therapeutics | Series C | $100M | Sep 2025 |
 Cardiac Dimensions | Series E | $53M | Mar 2025 |
 Arbor Biotechnologies | Series C | $73.9M | Mar 2025 |
 VitalConnect | Series F | $30M | Jan 2025 |
 Insightec | Growth | $150M | Jun 2024 |
 Transcarent | Series D | $126M | May 2024 |
 Alumis | Series C | $259M | Mar 2024 |
 ProfoundBio | Series B | $112M | Feb 2024 |
 Transcarent | Series D | $126M | Jan 2024 |
 Lightforce Orthodontics | Series D | $80M | Aug 2023 |
 Relievant Medsystems | Series G | $50M | Apr 2023 |
| RRelievant Medsystems, Inc. | Series G | $50M | Apr 2023 |
 Cargo Therapeutics | Series A | $200M | Mar 2023 |
 Ceribell | Series C | $50M | Sep 2022 |
 RayzeBio | Series D | $160M | Jan 2022 |
| Transcarent | Series C | — | Jan 2022 |
| Arbor Biotechnologies | Series B | $215M | Nov 2021 |
 Shoreline Biosciences | Series D | $140M | Nov 2021 |
 Elligo Health Research | Series E | $135M | Sep 2021 |
 Elligo | Series E | $135M | Sep 2021 |
 Sonoma Biotherapeutics | Series B | $265M | Aug 2021 |
Page 1 of 3
Top Co-Investors
T. Rowe Price9 shared
Cormorant Asset Management8 shared
Venrock6 shared
Perceptive Advisors6 shared
Sofinnova Partners5 shared
Norwest Venture Partners5 shared
Surveyor Capital5 shared
ARCH Venture Partners5 shared
RA Capital Management5 shared
EDBI4 shared
New Enterprise Associates4 shared
Omega Funds4 shared
Catalio Capital Management4 shared
OrbiMed4 shared
Merck Global Health Innovation Fund4 shared
Morgan Stanley Expansion Capital4 shared
Fidelity Investments3 shared
Gilmartin Capital3 shared
Lightstone Ventures3 shared
Last updated: 7 September 2026